title: Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
abstract: The Taq1A polymorphism in the dopamine D2 receptor (DRD2) gene could be related to the response to antipsychotics. We examined the effects of the Taq1A polymorphism on the plasma monoamine metabolites during the treatment of schizophrenia with aripiprazole, a DRD2 partial agonist. Thirty Japanese patients with schizophrenia were treated with aripiprazole for 6 weeks. We measured plasma levels of homovanillic acid (pHVA) and 3-methoxy-4hydroxyphenylglycol (pMHPG) before and after treatment. The Taq1A polymorphism was genotyped with polymerase chain reaction. Aripiprazole improved the acute symptoms of schizophrenia and decreased pHVA in responders (P = 0.023) but not in nonresponders (P = 0.28). Although A1 allele carriers showed a tendency to respond to aripiprazole (61.5%) compared to A1 allele noncarriers (29.4%) (P = 0.078), there was not statistically significant difference in the response between the 2 genotype groups. There were significant effect for response (P = 0.013) and genotype × response interaction (P = 0.043) on the change of pHVA. The changes of pHVA differ between responders and nonresponders in A1 allele carriers but not in A1 allele noncarriers. There were no genotype or response effects or genotype × response interaction on the changes of the plasma levels of 3-methoxy-4hydroxyphenylglycol. Our preliminary results suggest that Taq1A polymorphism may be partly associated with changes in pHVA during acute schizophrenia.
authors.affiliation: Department of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan. itaru@fmu.ac.jp
authors.forename: Itaru
authors.initials: I
authors.lastname: Miura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takeuchi
authors.forename: Akihiko
authors.initials: A
authors.lastname: Katsumi
authors.forename: Azuma
authors.initials: A
authors.lastname: Mori
authors.forename: Keiko
authors.initials: K
authors.lastname: Kanno
authors.forename: Qiaohui
authors.initials: Q
authors.lastname: Yang
authors.forename: Hirobumi
authors.initials: H
authors.lastname: Mashiko
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Numata
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Niwa
mesh_terms: D000208:Acute Disease; D000328:Adult; D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D005260:Female; D006580:Genetic Carrier Screening; D005838:Genotype; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D007564:Japan; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood*; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011110:Polymorphism, Genetic / Q000235:genetics*; D011569:Psychiatric Status Rating Scales; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000235:genetics*; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics*; D019914:Taq Polymerase / Q000235:genetics*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D008734:Methoxyhydroxyphenylglycol; D000068180:Aripiprazole; D019914:Taq Polymerase; D006719:Homovanillic Acid